Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial

BACKGROUND: The activity of palbociclib as a single agent in advanced breast cancer has not been extensively studied, with the only available clinical data limited to heavily pretreated patients. Preclinical data suggests palbociclib may partially reverse endocrine resistance, though this hypothesis...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Ann Oncol
Hoofdauteurs: Malorni, L, Curigliano, G, Minisini, A M, Cinieri, S, Tondini, C A, D’Hollander, K, Arpino, G, Bernardo, A, Martignetti, A, Criscitiello, C, Puglisi, F, Pestrin, M, Sanna, G, Moretti, E, Risi, E, Biagioni, C, McCartney, A, Boni, L, Buyse, M, Migliaccio, I, Biganzoli, L, Di Leo, A
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Oxford University Press 2018
Onderwerpen:
Original Articles
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6454527/
https://ncbi.nlm.nih.gov/pubmed/29893790
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdy214
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items